Bruker Corp's revenue was $3.44bn in fiscal 2025, up 2.1% on the year before. Since fiscal 2009 ($1.11bn) it has grown at a compound 7.3% a year. Over the last twelve months it was $3.50bn.
Revenue history
US$ millions unless shown otherwise.
Fiscal years, plus the last twelve months (LTM) when newer.
Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.
Where the revenue comes from
Fiscal year to December 31, 2025
Bsi Calid$1.2B
Bsi Nano$1.1B
Bsi Biospin$879M
Energy and Supercon Technologies$263M
Segments
Line of business
Revenue
Share
YoY
Bsi Calid
$1.2B
35.2%
▲ 10.7%
Bsi Nano
$1.1B
31.6%
▼ 1.3%
Bsi Biospin
$879M
25.6%
▼ 3.0%
Energy and Supercon Technologies
$263M
7.7%
▼ 2.1%
Products$2.8B
Other$670M
Products and services
Line of business
Revenue
Share
YoY
Products
$2.8B
80.5%
▲ 0.3%
Other
$670M
19.5%
▲ 10.4%
Europe Excluding Germany$950M
United States$891M
Asia Pacific Excluding China$553M
China$476M
Germany$297M
Other Country$270M
Geography
Region
Revenue
Share
YoY
Europe Excluding Germany
$950M
27.7%
▲ 8.8%
United States
$891M
25.9%
▼ 5.0%
Asia Pacific Excluding China
$553M
16.1%
▲ 6.6%
China
$476M
13.8%
▲ 1.0%
Germany
$297M
8.6%
▼ 4.4%
Other Country
$270M
7.8%
▲ 5.9%
From Bruker Corp's 10-K filed February 27, 2026, as tagged in the filing.
View filing. Indented rows are part of the
line above; their share is of that line. In the bars, the
faint bar behind is the year before.
Revenue against peers
Life Sciences Tools & Services: the closest covered companies by revenue. Last twelve months.
Figures from Bruker Corp's SEC filings (10-K and 10-Q), retrieved October 20, 2026.
How we read and check them: methodology and data sources.
Not investment advice. Back to Bruker Corp.